Goldman Sachs Group Inc Supernus Pharmaceuticals, Inc. Transaction History

Goldman Sachs Group Inc

$605 Billion
Q3 2024

A detailed history of Goldman Sachs Group Inc transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 899,637 shares of SUPN stock, worth $32.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

899,637

Previous 590,333 52.39%

Holding current value

$32.5 Million

Previous $15.8 Million 77.63%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$25.77 - $35.16 $7.97 Million - $10.9 Million	309,304 Added 52.39%	899,637 $28.1 Million
Q2 2024 Aug 13, 2024	BUY	$25.99 - $33.85 $7.16 Million - $9.32 Million	275,439 Added 87.47%	590,333 $15.8 Million
Q1 2024 May 15, 2024	BUY	$27.11 - $35.17 $2.05 Million - $2.66 Million	75,763 Added 31.68%	314,894 $10.7 Million
Q4 2023 Feb 13, 2024	BUY	$22.72 - $29.68 $1.86 Million - $2.43 Million	81,821 Added 52.01%	239,131 $6.92 Million
Q3 2023 May 14, 2024	SELL	$27.57 - $32.91 $2.26 Million - $2.69 Million	-81,821 Reduced 34.22%	157,310 $4.34 Million
Q3 2023 Nov 14, 2023	SELL	$27.57 - $32.91 $933,602 - $1.11 Million	-33,863 Reduced 17.71%	157,310 $4.34 Million
Q2 2023 May 14, 2024	SELL	$29.91 - $38.73 $2.77 Million - $3.59 Million	-92,608 Reduced 32.63%	191,173 $5.75 Million
Q2 2023 Aug 14, 2023	SELL	$29.91 - $38.73 $2.77 Million - $3.59 Million	-92,608 Reduced 32.63%	191,173 $5.75 Million
Q1 2023 May 14, 2024	SELL	$34.93 - $42.03 $1.23 Million - $1.47 Million	-35,078 Reduced 11.0%	283,781 $10.3 Million
Q1 2023 May 11, 2023	SELL	$34.93 - $42.03 $1.23 Million - $1.47 Million	-35,078 Reduced 11.0%	283,781 $10.3 Million
Q4 2022 May 14, 2024	BUY	$31.09 - $37.88 $3.02 Million - $3.68 Million	97,127 Added 43.8%	318,859 $11.4 Million
Q4 2022 Feb 13, 2023	BUY	$31.09 - $37.88 $3.02 Million - $3.68 Million	97,127 Added 43.8%	318,859 $11.4 Million
Q3 2022 May 14, 2024	SELL	$28.79 - $35.41 $2.47 Million - $3.04 Million	-85,751 Reduced 27.89%	221,732 $7.51 Million
Q3 2022 Nov 10, 2022	SELL	$28.79 - $35.41 $2.47 Million - $3.04 Million	-85,751 Reduced 27.89%	221,732 $7.51 Million
Q2 2022 May 14, 2024	BUY	$25.33 - $34.25 $1.73 Million - $2.34 Million	68,352 Added 28.58%	307,483 $8.89 Million
Q2 2022 Aug 15, 2022	SELL	$25.33 - $34.25 $6.15 Million - $8.31 Million	-242,598 Reduced 44.1%	307,483 $8.89 Million
Q1 2022 May 16, 2022	BUY	$28.51 - $32.9 $8.15 Million - $9.4 Million	285,737 Added 108.09%	550,081 $17.8 Million
Q4 2021 Feb 14, 2022	BUY	$26.37 - $34.22 $72,095 - $93,557	2,734 Added 1.05%	264,344 $7.71 Million
Q3 2021 Nov 10, 2021	BUY	$23.54 - $31.39 $6.16 Million - $8.21 Million	261,610 New	261,610 $6.98 Million

Others Institutions Holding SUPN

# of Institutions

282

Shares Held

60.9M

Call Options Held

27.7K

Put Options Held

11.3K

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.93B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc Supernus Pharmaceuticals, Inc. Transaction History